EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Poll|October 24, 2014
“Swimsuit Area” Rash: Your Dx?
A 66-year-old woman had a mildly pruritic rash on the buttocks, lower back, abdomen, and upper posterior thighs. The eruption had been present for approximately 18 months. Your diagnosis?
Advertisement
A 66-year-old woman had a mildly pruritic rash on the buttocks, lower back, abdomen, and upper posterior thighs. The eruption had been present for approximately 18 months.
Your diagnosis?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
2
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
5 FDA Decisions for Primary Care to Know from September 2026
5